EP4330675A1 - Patient side in vitro screening kit for rapid diagnosis of a pathology - Google Patents
Patient side in vitro screening kit for rapid diagnosis of a pathologyInfo
- Publication number
- EP4330675A1 EP4330675A1 EP22725534.6A EP22725534A EP4330675A1 EP 4330675 A1 EP4330675 A1 EP 4330675A1 EP 22725534 A EP22725534 A EP 22725534A EP 4330675 A1 EP4330675 A1 EP 4330675A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- recesses
- support
- kit according
- kit
- antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000338 in vitro Methods 0.000 title abstract description 3
- 230000007170 pathology Effects 0.000 title description 13
- 238000003745 diagnosis Methods 0.000 title description 9
- 238000012216 screening Methods 0.000 title description 5
- 239000000427 antigen Substances 0.000 claims abstract description 14
- 102000036639 antigens Human genes 0.000 claims abstract description 14
- 108091007433 antigens Proteins 0.000 claims abstract description 14
- 239000012472 biological sample Substances 0.000 claims abstract description 5
- 230000004044 response Effects 0.000 claims abstract description 3
- 102000036673 PRAME Human genes 0.000 claims abstract 3
- 108060006580 PRAME Proteins 0.000 claims abstract 3
- 239000013068 control sample Substances 0.000 claims abstract 2
- 239000000126 substance Substances 0.000 claims description 11
- 230000002255 enzymatic effect Effects 0.000 claims description 7
- 206010027145 Melanocytic naevus Diseases 0.000 claims description 6
- 239000000243 solution Substances 0.000 claims description 5
- 239000000137 peptide hydrolase inhibitor Substances 0.000 claims description 4
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 claims description 3
- 239000000853 adhesive Substances 0.000 claims description 3
- 230000001070 adhesive effect Effects 0.000 claims description 3
- 239000007853 buffer solution Substances 0.000 claims description 3
- 238000006243 chemical reaction Methods 0.000 claims description 3
- 125000006850 spacer group Chemical group 0.000 claims description 3
- 102000004190 Enzymes Human genes 0.000 claims description 2
- 108090000790 Enzymes Proteins 0.000 claims description 2
- 241000894007 species Species 0.000 claims description 2
- 241001465754 Metazoa Species 0.000 claims 2
- 230000009089 cytolysis Effects 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 210000000981 epithelium Anatomy 0.000 claims 1
- 230000003100 immobilizing effect Effects 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 abstract description 22
- 238000000034 method Methods 0.000 abstract description 13
- 239000003153 chemical reaction reagent Substances 0.000 abstract description 4
- 238000012286 ELISA Assay Methods 0.000 abstract 1
- BQCIDUSAKPWEOX-UHFFFAOYSA-N 1,1-Difluoroethene Chemical compound FC(F)=C BQCIDUSAKPWEOX-UHFFFAOYSA-N 0.000 description 21
- 206010028980 Neoplasm Diseases 0.000 description 17
- 201000011510 cancer Diseases 0.000 description 15
- 239000007788 liquid Substances 0.000 description 10
- 238000007654 immersion Methods 0.000 description 6
- 239000000872 buffer Substances 0.000 description 5
- 239000010410 layer Substances 0.000 description 5
- 239000012528 membrane Substances 0.000 description 5
- 210000003491 skin Anatomy 0.000 description 5
- 238000002965 ELISA Methods 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 238000011534 incubation Methods 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 239000000523 sample Substances 0.000 description 4
- 239000000758 substrate Substances 0.000 description 4
- 238000005406 washing Methods 0.000 description 4
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 3
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 3
- 241000283707 Capra Species 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 241000283973 Oryctolagus cuniculus Species 0.000 description 3
- 102000003992 Peroxidases Human genes 0.000 description 3
- 230000003321 amplification Effects 0.000 description 3
- 208000030381 cutaneous melanoma Diseases 0.000 description 3
- 238000013399 early diagnosis Methods 0.000 description 3
- 238000003199 nucleic acid amplification method Methods 0.000 description 3
- 108040007629 peroxidase activity proteins Proteins 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 201000003708 skin melanoma Diseases 0.000 description 3
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- 206010010356 Congenital anomaly Diseases 0.000 description 2
- 102000018071 Immunoglobulin Fc Fragments Human genes 0.000 description 2
- 108010091135 Immunoglobulin Fc Fragments Proteins 0.000 description 2
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
- RIIWUGSYXOBDMC-UHFFFAOYSA-N benzene-1,2-diamine;hydron;dichloride Chemical compound Cl.Cl.NC1=CC=CC=C1N RIIWUGSYXOBDMC-UHFFFAOYSA-N 0.000 description 2
- 239000012620 biological material Substances 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 238000005755 formation reaction Methods 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 239000006166 lysate Substances 0.000 description 2
- 230000002934 lysing effect Effects 0.000 description 2
- 239000012139 lysis buffer Substances 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 239000004745 nonwoven fabric Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 238000005070 sampling Methods 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- PCTMTFRHKVHKIS-BMFZQQSSSA-N (1s,3r,4e,6e,8e,10e,12e,14e,16e,18s,19r,20r,21s,25r,27r,30r,31r,33s,35r,37s,38r)-3-[(2r,3s,4s,5s,6r)-4-amino-3,5-dihydroxy-6-methyloxan-2-yl]oxy-19,25,27,30,31,33,35,37-octahydroxy-18,20,21-trimethyl-23-oxo-22,39-dioxabicyclo[33.3.1]nonatriaconta-4,6,8,10 Chemical compound C1C=C2C[C@@H](OS(O)(=O)=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2.O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 PCTMTFRHKVHKIS-BMFZQQSSSA-N 0.000 description 1
- UAIUNKRWKOVEES-UHFFFAOYSA-N 3,3',5,5'-tetramethylbenzidine Chemical compound CC1=C(N)C(C)=CC(C=2C=C(C)C(N)=C(C)C=2)=C1 UAIUNKRWKOVEES-UHFFFAOYSA-N 0.000 description 1
- XZKIHKMTEMTJQX-UHFFFAOYSA-L 4-nitrophenyl phosphate(2-) Chemical compound [O-][N+](=O)C1=CC=C(OP([O-])([O-])=O)C=C1 XZKIHKMTEMTJQX-UHFFFAOYSA-L 0.000 description 1
- QRXMUCSWCMTJGU-UHFFFAOYSA-N 5-bromo-4-chloro-3-indolyl phosphate Chemical compound C1=C(Br)C(Cl)=C2C(OP(O)(=O)O)=CNC2=C1 QRXMUCSWCMTJGU-UHFFFAOYSA-N 0.000 description 1
- 206010023256 Juvenile melanoma benign Diseases 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 208000000453 Skin Neoplasms Diseases 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- QPMSXSBEVQLBIL-CZRHPSIPSA-N ac1mix0p Chemical compound C1=CC=C2N(C[C@H](C)CN(C)C)C3=CC(OC)=CC=C3SC2=C1.O([C@H]1[C@]2(OC)C=CC34C[C@@H]2[C@](C)(O)CCC)C2=C5[C@]41CCN(C)[C@@H]3CC5=CC=C2O QPMSXSBEVQLBIL-CZRHPSIPSA-N 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 150000004945 aromatic hydrocarbons Chemical class 0.000 description 1
- OHDRQQURAXLVGJ-HLVWOLMTSA-N azane;(2e)-3-ethyl-2-[(e)-(3-ethyl-6-sulfo-1,3-benzothiazol-2-ylidene)hydrazinylidene]-1,3-benzothiazole-6-sulfonic acid Chemical compound [NH4+].[NH4+].S/1C2=CC(S([O-])(=O)=O)=CC=C2N(CC)C\1=N/N=C1/SC2=CC(S([O-])(=O)=O)=CC=C2N1CC OHDRQQURAXLVGJ-HLVWOLMTSA-N 0.000 description 1
- OHDRQQURAXLVGJ-AXMZSLBLSA-N azane;(2z)-3-ethyl-2-[(z)-(3-ethyl-6-sulfo-1,3-benzothiazol-2-ylidene)hydrazinylidene]-1,3-benzothiazole-6-sulfonic acid Chemical compound [NH4+].[NH4+].S/1C2=CC(S([O-])(=O)=O)=CC=C2N(CC)C\1=N\N=C1/SC2=CC(S([O-])(=O)=O)=CC=C2N1CC OHDRQQURAXLVGJ-AXMZSLBLSA-N 0.000 description 1
- 239000000090 biomarker Substances 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 230000002051 biphasic effect Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 208000035269 cancer or benign tumor Diseases 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 238000004737 colorimetric analysis Methods 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 230000002380 cytological effect Effects 0.000 description 1
- 210000004207 dermis Anatomy 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 230000005484 gravity Effects 0.000 description 1
- 230000036571 hydration Effects 0.000 description 1
- 238000006703 hydration reaction Methods 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 230000000642 iatrogenic effect Effects 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 230000000366 juvenile effect Effects 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- HWYHZTIRURJOHG-UHFFFAOYSA-N luminol Chemical compound O=C1NNC(=O)C2=C1C(N)=CC=C2 HWYHZTIRURJOHG-UHFFFAOYSA-N 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- RARSHUDCJQSEFJ-UHFFFAOYSA-N p-Hydroxypropiophenone Chemical compound CCC(=O)C1=CC=C(O)C=C1 RARSHUDCJQSEFJ-UHFFFAOYSA-N 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000009862 primary prevention Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000011265 semifinished product Substances 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 238000005063 solubilization Methods 0.000 description 1
- 230000007928 solubilization Effects 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 238000003856 thermoforming Methods 0.000 description 1
- 239000000107 tumor biomarker Substances 0.000 description 1
- 239000000439 tumor marker Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/5743—Specifically defined cancers of skin, e.g. melanoma
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L3/00—Containers or dishes for laboratory use, e.g. laboratory glassware; Droppers
- B01L3/50—Containers for the purpose of retaining a material to be analysed, e.g. test tubes
- B01L3/508—Containers for the purpose of retaining a material to be analysed, e.g. test tubes rigid containers not provided for above
- B01L3/5085—Containers for the purpose of retaining a material to be analysed, e.g. test tubes rigid containers not provided for above for multiple samples, e.g. microtitration plates
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L9/00—Supporting devices; Holding devices
- B01L9/52—Supports specially adapted for flat sample carriers, e.g. for plates, slides, chips
- B01L9/523—Supports specially adapted for flat sample carriers, e.g. for plates, slides, chips for multisample carriers, e.g. used for microtitration plates
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L2200/00—Solutions for specific problems relating to chemical or physical laboratory apparatus
- B01L2200/16—Reagents, handling or storing thereof
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L2300/00—Additional constructional details
- B01L2300/06—Auxiliary integrated devices, integrated components
- B01L2300/0672—Integrated piercing tool
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L2400/00—Moving or stopping fluids
- B01L2400/06—Valves, specific forms thereof
- B01L2400/0677—Valves, specific forms thereof phase change valves; Meltable, freezing, dissolvable plugs; Destructible barriers
- B01L2400/0683—Valves, specific forms thereof phase change valves; Meltable, freezing, dissolvable plugs; Destructible barriers mechanically breaking a wall or membrane within a channel or chamber
Definitions
- the present invention is in the field of the rapid diagnosis of a pathology, e.g. of a cancer pathology such as melanoma using a kit, stable at room temperature.
- the invention refers to a method that can also be performed in environments outside the laboratory, "patient side" with immediate response of a chemocolorimetric, bioluminescent or digital reader for the diagnosis and/or prediction of the risk of developing melanoma comprising the detection in cell extracts of certain cancer markers using immunoassays, such as ELISA (enzyme linked immunosorbent assay).
- Melanoma is a cancer that affects the skin, among all types of skin cancers, it is the least common but also the most dangerous because it can grow quickly and also invade the surrounding tissues. It is a naked eye visible cancer and it originates from a pre-existing naevus that changes shape or colour or from the appearance of a new naevus on intact skin. It is always a malignant neoplasm, in fact it is never possible to define a benign melanoma, at most we can speak of a benign naevus that does not have the characteristics of a melanoma.
- Cutaneous melanomas originate both on intact skin and from pre-existing naevi, which are present from birth or early childhood (congenital) or appear during the course of life (acquired). Cutaneous melanoma accounts for 9% of juvenile cancers in men and 7% in women; it is quite rare in children and mainly affects around 45-50 years of age, although the average age at diagnosis has dropped in recent decades. In Italy there are an estimated 7,300 new cases each year among men and 6,700 among women, the incidence is constantly growing and has even doubled in the last 10 years.
- a useful and easy to remember method for recognizing a suspicious naevus is the abbreviation ABCD which lists its characteristics: A as an asymmetry of the shape, B as irregular edges, C as a variable colour, D as an increasing size both in width and in thickness.
- ABCD A useful and easy to remember method for recognizing a suspicious naevus
- a useful and easy to remember method for recognizing a suspicious naevus is the abbreviation ABCD which lists its characteristics: A as an asymmetry of the shape, B as irregular edges, C as a variable colour, D as an increasing size both in width and in thickness.
- congenital naevi are rounded, have a uniform colour and do not undergo changes over time.
- Primary melanoma refers to the first appearance of melanoma and can usually be seen on the skin surface. Melanoma can quickly spread to any part of the body, so it's important to spot and treat it in its early stage. When melanoma is identified in its early stages, there is a very good chance that all of the cancer can be surgically removed before it spreads to other parts of the body and in that case the chances of long-term survival are excellent. Rapid screening therefore becomes of primary importance to direct the doctor towards the treatment plan. There are currently no scientifically reliable, non-invasive screening methods for the prevention of melanoma.
- the present invention refers to an innovative kit with ELISA technique and chemocolorimetric, bioluminescent or digital result for the early diagnosis of a pathology, preferably of a cancer pathology such as a melanoma.
- the kit uses reagents that are stable at room temperature, is rapid, sensitive, specific, transportable, cheap and non-invasive.
- the kit of the invention allows the determination of a specific antigen associated with a pathology of interest, in the case of cancer pathologies such as melanoma, PRAME (PReferentially expressed Antigen Melanoma) by means of a double use of primary antibodies to ensure unequivocal the specificity and sensitivity of the signal.
- a first polyclonal primary antibody e.g.
- rabbit anti-PRAME will be adhered to a PVDF membrane, a second primary monoclonal antibody e.g. of mouse anti- PRAME will be used in test tube. Subsequently, secondary anti-mouse antibodies conjugated with an enzymatic signal amplification system, in particular alkaline phosphatase or peroxidase, will be used.
- an enzymatic signal amplification system in particular alkaline phosphatase or peroxidase
- the kit comprises at least one substrate such as ABTS (2,2'-Azinobis [3-ethylbenzothiazoline- 6-sulfonic acid] -diammonium salt), OPD (o-phenylenediamine dihydrochloride), TMB (3 , 3 ', 5,5'-tetramethylbenzidine), p-Nitrophenyl Phosphate (PNPP).
- substrate such as ABTS (2,2'-Azinobis [3-ethylbenzothiazoline- 6-sulfonic acid] -diammonium salt
- OPD o-phenylenediamine dihydrochloride
- TMB 3 , 3 ', 5,5'-tetramethylbenzidine
- PNPP p-Nitrophenyl Phosphate
- the kit uses dried or lyophilized antibodies, stable at room temperature, which at the time of use are solubilized in a buffer solution present in the kit.
- the present invention is configured as an effective diagnostic aid for a pathology e.g. a cancer pathology such as melanoma, which does not require laboratory aids and provides immediate answers.
- a pathology e.g. a cancer pathology such as melanoma
- the invention also refers to the creation of an innovative kit built by assembling commercially available and custom made semi-finished products.
- the kit comprises a hard bristle cytobrush useful for taking the biological sample e.g. at the level of the epidermis and the necessary to allow the professional (Doctor or person entitled to use by the regulations in force in the area of use) to analyse it and verify the presence of the biomarker e.g. of the cancer biomarker or to process it through a specific automatic development device.
- the product has an extremely simple method of use.
- kit equipped with a cytobrush or other known device eg. stick intended for the collection of biological material and, strip or strips of PVDF (pol vinylidene fluoride) suitably mounted on a rigid support and preloaded test tubes of powders of protease inhibitors in the dried state, lyophilized and/or dried antibodies, tubes preloaded with liquids, liquids for washing, developing and detecting the enzymatic signal and devices for the solubilization of preloaded reagents, in particular two-phase break-out capsules.
- a sterile medical patch can be used, e.g. comprising an adhesive support in non-woven fabric.
- gauze preferably also of non- woven fabric, combined with a substance with antibacterial activity, e.g. 0.5% chlorhexidine digluconate.
- Kit operation diagram dissolve the reagents present in the wells/station P in the dried and or lyophilized state upon opening the kit by perforating the overlying re ervoirs S having function as break-out cap (figure above). Collection of potentially malignant cells from the dermis with the specific tools to carry out the collection; immersion of the same in the well/station zero, containing a protease inhibitor and a buffer lysing the cells collected by means of the collection device.
- Transfer of the lysate from the well/station zero to the well/station one preferably empty when the user opens the kit; immersion of the PVDF strip in the well/station one for the recognition of the cancer antigen by the specific primary antibodies immobilized on the PVDF strip.
- the formation of immunecomplexes takes place on the strip if there is the presence of the cancer protein in the sample collected.
- the PVDF strip with the immobilized immunecomplexes is immersed into well/station number two containing a primary target solution equally specific for the antigen e.g. cancer, but of a different species from those adsorbed on the membrane.
- the use of the second on the series of primary antibodies has the purpose of allowing a specific recognition by the secondary antibody used in the next phase, preventing the latter from binding to all the useful primary adsorbed on the PVDF strip. Washings with T-PBS will take place in wells/stations number three and four.
- the wells and/or reservoirs are preferably produced based on aromatic hydrocarbons so as to be hydrophobic and allow a total convergence of the quantities of fluid at the bottom of the recesses and, even more preferably, produced as a monolayer for example of polystyrene.
- each well or recess again in order to favour the convergence towards the bottom of the liquid substances in use, has convex walls observing the inside of the recesses.
- the support 10 of figure 2 defines recesses 11 for liquid substances and recesses 12 for powdered or dried substances e.g. protease inhibitor/dried antibodies.
- the kit comprises a support 20 superimposed on the support 10 and having corresponding recesses 21 containing pre-defined quantities i.e. dosed liquids e.g. a lysis buffer and a buffer liquid, to define a two-phase container in use.
- recesses 12 house recesses 21 when support 20 rests on support 10.
- Support 20 is preferably produced by thermoforming like support 10 and, even more preferably, support 20 is of the same polymeric material as support 10.
- peelable layer 13 comprises a gripping appendage 14 e.g. having a smaller transverse dimension but, in any case, such as to close a recess 11.
- Peelable layer 13 has one or more openings A to surround, when it adheres to support 10, recesses 12 and thus allow recesses 21 to be housed in the latter when support 20 rests on support 10.
- Support 20 is also closed by means of a corresponding peelable closing layer 22 bearing symbols SI, S2, S3 to identify, each one, a preferred point for breaking layer 22 and underlying recess 21 in order to perform the mixing of the substances.
- recesses 21 contain a pre-defined quantity of liquid and this helps the complete gravity fall into recess 12 of the liquid: this is particularly important when, as in this case, the metered quantities are of a few micrograms and/or as in this case of 280 picograms.
- symbols SI, S2, S3 provide a perforation sequence, which is preferably performed by means of a suitable tool 30 ( Figure 3).
- the tool has a shaped grip, for example triangular, having a dimension such as to contact during the perforation an edge of recesses 21, also having a calibrated geometry and dimension.
- the tool is in the position of maximum advancement towards the bottom of corresponding recess 12 and also a height between a perforation head of the tool and the abutment position between the shaped grip and the edge of recess 21 is pre-defined in so as to perforate recess 21 in a pre-defined manner and depth independent of the user that performs the operation.
- Figure 3 further illustrates a stick 40 on which the primary antibodies, e.g. through a membrane facing a window 41, are applied. Through the window 41, the antibodies are exposed to the substances contained in recesses 11, 12 to define any antigens, e.g. cancer antigens.
- Figure 3 further illustrates an exploded view of the main components of the kit, i.e. supports 10 and 20 and a base 50 preferably with a double basin.
- Supports 10 and 20 are preferably arranged in pocket 51 so that the recesses 11, 12 are suspended when support 10 abuts against an edge of the pocket.
- Stick 40, perforation tool 30, the collection tool and a Pasteur pipette are preferably arranged in pocket 52.
- Base 50 is preferably closed by means of a preferably square-shaped band casing which slides laterally with reference to the point of view of Figure 3.
- the kit can be adapted e.g. by number of biphasic containers and/or recesses, dehydrated or dried substances and liquids, to test methods made for other diseases.
- support 20 or in an embodiment not shown support 10, comprises one or more spacer projections D having a calibrated vertical dimension and such as to define the adapted position wherein recesses 21 are housed in the corresponding recesses 12.
- recesses 21 have a vertical dimension greater than that of the spacer projections D so that an end portion T of recesses 21 is within recesses 12.
- pocket 52 houses at least one pipette, preferably a Pasteur pipette, in order to transfer the liquid from one recess 11, 12 to the other.
- pocket 51 has a stepped profile and, correspondingly, support 10 has a lower width LI so as to rest a first step G1 of a width L2 of support 20. The latter abuts on a step G2 arranged above the step G1 when the kit is placed on a table.
- the method for the early diagnosis and monitoring of melanoma of the present patent provides for the detection of the antigen expressed mainly in human melanomas (PRAME) in samples collected from suspected naevi of the subject under examination.
- PRAME marker in the context of the present invention also includes variants, isoforms etc. Said marker is characterized by an NCBI Access number and the antibodies used for the preparation of the device preferably refer to the following collected purely by way of example: PRAME Monoclonal Antibody (CL5148) (Product # MA5-31409); PRAME Polyclonal antibody, N-term Cat No. GTX45142; Mouse IgG (Fc fragment) antibody, F (ab') 2 fragment, pre-adsorbed (AP) Cat No. GTX25880 (Goat, Polyclonal) or Goat Anti-Mouse IgG antibody (HRP) Cat No. GTX 213211-01.
- the steps for preparing the PVDF strip armed with the primary antibodies of interest in sequence are as follows: hydration of the PVDF strip (ThermoFisher Scientific Catalog Number LC2002) with methanol for 5 min; washing with water for 5 min; two washes with PBS for 5 min; incubation with protein A from Staphylococcus aureus (Sigma- Aldrich, 10 pg / mL) for 1 h in PBS; two washes with PBS; blocking with 3% BSA solution in PBS for 1 h; three washes with PBS for 5 min; assembly of the PVDF; incubation with rabbit antibody solution (PRAME Rabbit Polyclonal antibody, N-term Cat No.
- the Positive Control is an anti-actin antibody (Sigma - Aldrich, A2066).
- kits equipped with cytobrush for the collection of biological material and support for the PVDF (Immobilon) strip armed with the primary antibodies of interest are described below.
- the kit box is organized in rows of nine wells/stations containing buffers, lysing systems, detection systems stable at room temperature and dried/lyophilized antibodies stable at room temperature (Fig. 1).
- EXAMPLE 4 How to use the kit The following are the operational steps which in sequence allow the diagnosis of melanoma or another pathology: collecting the sample from the suspect naevus, using the collection tools within the kit; immersing the biological sample for 15 min in the well/station number zero containing the lysis buffer; extracting the tool and transfering the lysate to the well/station number one; opening the package of the support to which the PVDF membrane is adhered; immersing the support with the PVDF strip for 5 min in the first well/station number one to allow the interaction of the proteins (antigens) with the primary antibodies adhered to the PVDF strip, in order to form the immunocomplex (purely by way of example: PRAME Polyclonal antibody, N-term Cat No.
- the PVDF membrane is i mersed in well/station number two containing in solution the second primary mouse antibody (purely by way of example: PRAME Monoclonal Antibody (CL5148) (Product # MA5-31409) for the reaction with the immobilized immunocomplex; proceed with 2 washes of the support with the PVDF strip in wells containing T-PBS-buffer to eliminate the non- specifically attached proteins to the immunocomplex; immersion of the support with the PVDF strip for 10 min in well/station number five containing the mouse secondary antibody (purely by way of example: Mouse IgG (Fc fragment) antibody, F (ab') 2 fragment, pre-adsorb and (AP) Cat No.
- GTX25880 Goat, Polyclonal
- a detector enzymatic system alkaline phosphatase or peroxidase
- BCIP / NBT stable at room temperature or Luminol ECL substrate
- the colorimetric test will be carried out at room temperature, corresponding to a temperature range between 20° and 30° C.
- the use, in the kit, of a secondary antibody having a detector enzymatic system (alkaline phosphatase or peroxidase) has in this temperature range the maximum enzymatic activity, thus allowing an optimal signal amplification.
- EXAMPLE 6 Use of the kit of the invention for the identification of an individual with melanoma.
- the Operator After having highlighted the suspected lesion by means of an epilluminescence examination, places the cytobrush on it and performs the sampling maneuver.
- the maneuver consists in rotating the cytobrush on itself 4-5 times, exerting constant pressure.
- This method of cell collection is totally safe and free from any iatrogenic type problem.
- This technique can also be used to perform mass screening on populations, given that such neoplasm ranks fourth by incidence in the world. Thanks to this protocol it is possible to implement the correct principles for primary prevention.
- the exam can be performed by qualified personnel after having performed a learning trial on the collection method.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Oncology (AREA)
- Cell Biology (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Hospice & Palliative Care (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Clinical Laboratory Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
An in vitro method to identify melanoma in humans using a kit that allows to perform a patient side ELISA assay, with dried or lyophilized reagents, which are brought back into solution and/or mixed at the time of use of the kit, obtaining a qualitative response immediate chemocolorimetric, biolumine scent, comprises the steps of: a) detecting and/or quantifying a specific antigen, for example expressed mainly in melanomas (PRAME) in a biological sample obtained from the subject; b) compare the result with a control sample; for example, the presence of PRAME indicates that the subject is suffering from melanoma.
Description
PATIENT SIDE IN VITRO SCREENING KIT FOR RAPID DIAGNOSIS OF A
PATHOLOGY
FIELD OF THE INVENTION
The present invention is in the field of the rapid diagnosis of a pathology, e.g. of a cancer pathology such as melanoma using a kit, stable at room temperature. In particular, the invention refers to a method that can also be performed in environments outside the laboratory, "patient side" with immediate response of a chemocolorimetric, bioluminescent or digital reader for the diagnosis and/or prediction of the risk of developing melanoma comprising the detection in cell extracts of certain cancer markers using immunoassays, such as ELISA (enzyme linked immunosorbent assay).
PRIOR ART
Melanoma is a cancer that affects the skin, among all types of skin cancers, it is the least common but also the most dangerous because it can grow quickly and also invade the surrounding tissues. It is a naked eye visible cancer and it originates from a pre-existing naevus that changes shape or colour or from the appearance of a new naevus on intact skin. It is always a malignant neoplasm, in fact it is never possible to define a benign melanoma, at most we can speak of a benign naevus that does not have the characteristics of a melanoma. Cutaneous melanomas originate both on intact skin and from pre-existing naevi, which are present from birth or early childhood (congenital) or appear during the course of life (acquired). Cutaneous melanoma accounts for 9% of juvenile cancers in men and 7% in women; it is quite rare in children and mainly affects around 45-50 years of age, although the average age at diagnosis has dropped in recent decades. In Italy there are an estimated 7,300 new cases each year among men and 6,700 among women, the incidence is constantly growing and has even doubled in the last 10 years.
The precancerous formations of melanoma do not cause symptoms but can be identified with careful monitoring of skin naevi. A useful and easy to remember method for
recognizing a suspicious naevus is the abbreviation ABCD which lists its characteristics: A as an asymmetry of the shape, B as irregular edges, C as a variable colour, D as an increasing size both in width and in thickness. In general, congenital naevi are rounded, have a uniform colour and do not undergo changes over time.
Primary melanoma refers to the first appearance of melanoma and can usually be seen on the skin surface. Melanoma can quickly spread to any part of the body, so it's important to spot and treat it in its early stage. When melanoma is identified in its early stages, there is a very good chance that all of the cancer can be surgically removed before it spreads to other parts of the body and in that case the chances of long-term survival are excellent. Rapid screening therefore becomes of primary importance to direct the doctor towards the treatment plan. There are currently no scientifically reliable, non-invasive screening methods for the prevention of melanoma.
Currently, the clear diagnosis of cutaneous melanoma requires a biopsy, wherein a tissue sample is taken and then analysed under a microscope. Therefore, there is a need to provide a method for an early diagnosis of melanoma that allows to identify subjects at risk of developing the pathology and to subject them to a diagnosis of certainty, based on histological sampling and anatomopathological confirmation.
In general, the preceding paragraph relating to diagnosis applies to numerous other cancer and non-cancer pathologies.
DESCRIPTION OF THE INVENTION
The present invention refers to an innovative kit with ELISA technique and chemocolorimetric, bioluminescent or digital result for the early diagnosis of a pathology, preferably of a cancer pathology such as a melanoma. The kit uses reagents that are stable at room temperature, is rapid, sensitive, specific, transportable, cheap and non-invasive. In particular, the kit of the invention allows the determination of a specific antigen associated with a pathology of interest, in the case of cancer pathologies such as melanoma, PRAME (PReferentially expressed Antigen Melanoma) by means of a double use of primary antibodies to ensure unequivocal the specificity and sensitivity of the signal. In particular, a first polyclonal primary antibody e.g. rabbit anti-PRAME will be adhered to a PVDF membrane, a second primary monoclonal antibody e.g. of mouse anti-
PRAME will be used in test tube. Subsequently, secondary anti-mouse antibodies conjugated with an enzymatic signal amplification system, in particular alkaline phosphatase or peroxidase, will be used. In order to react with such enzyme systems, the kit comprises at least one substrate such as ABTS (2,2'-Azinobis [3-ethylbenzothiazoline- 6-sulfonic acid] -diammonium salt), OPD (o-phenylenediamine dihydrochloride), TMB (3 , 3 ', 5,5'-tetramethylbenzidine), p-Nitrophenyl Phosphate (PNPP).
The kit uses dried or lyophilized antibodies, stable at room temperature, which at the time of use are solubilized in a buffer solution present in the kit.
The present invention is configured as an effective diagnostic aid for a pathology e.g. a cancer pathology such as melanoma, which does not require laboratory aids and provides immediate answers.
The invention also refers to the creation of an innovative kit built by assembling commercially available and custom made semi-finished products. The kit comprises a hard bristle cytobrush useful for taking the biological sample e.g. at the level of the epidermis and the necessary to allow the professional (Doctor or person entitled to use by the regulations in force in the area of use) to analyse it and verify the presence of the biomarker e.g. of the cancer biomarker or to process it through a specific automatic development device. The product has an extremely simple method of use.
The present invention is described below in non-limiting examples:
Components: kit equipped with a cytobrush or other known device eg. stick intended for the collection of biological material and, strip or strips of PVDF (pol vinylidene fluoride) suitably mounted on a rigid support and preloaded test tubes of powders of protease inhibitors in the dried state, lyophilized and/or dried antibodies, tubes preloaded with liquids, liquids for washing, developing and detecting the enzymatic signal and devices for the solubilization of preloaded reagents, in particular two-phase break-out capsules. As an alternative to the cytobrush, a sterile medical patch can be used, e.g. comprising an adhesive support in non-woven fabric. Optionally there is also a gauze, preferably also of non- woven fabric, combined with a substance with antibacterial activity, e.g. 0.5% chlorhexidine digluconate.
Figure 1. Kit operation diagram: dissolve the reagents present in the wells/station P in the dried and or lyophilized state upon opening the kit by perforating the overlying re ervoirs
S having function as break-out cap (figure above). Collection of potentially malignant cells from the dermis with the specific tools to carry out the collection; immersion of the same in the well/station zero, containing a protease inhibitor and a buffer lysing the cells collected by means of the collection device.
Transfer of the lysate from the well/station zero to the well/station one (generic embodiment example in the figure below) preferably empty when the user opens the kit; immersion of the PVDF strip in the well/station one for the recognition of the cancer antigen by the specific primary antibodies immobilized on the PVDF strip. In well/station one the formation of immunecomplexes takes place on the strip if there is the presence of the cancer protein in the sample collected.
Immersion of the PVDF strip in the well/station number two. The PVDF strip with the immobilized immunecomplexes is immersed into well/station number two containing a primary target solution equally specific for the antigen e.g. cancer, but of a different species from those adsorbed on the membrane. The use of the second on the series of primary antibodies has the purpose of allowing a specific recognition by the secondary antibody used in the next phase, preventing the latter from binding to all the useful primary adsorbed on the PVDF strip. Washings with T-PBS will take place in wells/stations number three and four.
Immersion in the well/station number five of the PVDF strip on which the immunecomplexes antigen/primary antibody are present to allow the interaction with the secondary antibodies conjugated to an enzymatic detection system; washings with T-PBS will take place in wells/stations number six and seven;
Bioluminescent colorimetric expression using the substrate stable at room temperature in well/station number eight.
Reading and interpretation of the result.
According to an embodiment (Figures 2 and 3), the wells and/or reservoirs are preferably produced based on aromatic hydrocarbons so as to be hydrophobic and allow a total convergence of the quantities of fluid at the bottom of the recesses and, even more preferably, produced as a monolayer for example of polystyrene. Furthermore, each well or recess, again in order to favour the convergence towards the bottom of the liquid substances in use, has convex walls observing the inside of the recesses. For example, the
support 10 of figure 2 defines recesses 11 for liquid substances and recesses 12 for powdered or dried substances e.g. protease inhibitor/dried antibodies. Furthermore, the kit comprises a support 20 superimposed on the support 10 and having corresponding recesses 21 containing pre-defined quantities i.e. dosed liquids e.g. a lysis buffer and a buffer liquid, to define a two-phase container in use. In this regard, recesses 12 house recesses 21 when support 20 rests on support 10. Support 20 is preferably produced by thermoforming like support 10 and, even more preferably, support 20 is of the same polymeric material as support 10.
Furthermore, support 10 is protected by a peelable covering layer 13 to hermetically close recesses 11. Preferably, peelable layer 13 comprises a gripping appendage 14 e.g. having a smaller transverse dimension but, in any case, such as to close a recess 11.
Peelable layer 13 has one or more openings A to surround, when it adheres to support 10, recesses 12 and thus allow recesses 21 to be housed in the latter when support 20 rests on support 10.
Support 20 is also closed by means of a corresponding peelable closing layer 22 bearing symbols SI, S2, S3 to identify, each one, a preferred point for breaking layer 22 and underlying recess 21 in order to perform the mixing of the substances. In particular, recesses 21 contain a pre-defined quantity of liquid and this helps the complete gravity fall into recess 12 of the liquid: this is particularly important when, as in this case, the metered quantities are of a few micrograms and/or as in this case of 280 picograms. Furthermore, as a whole, symbols SI, S2, S3 provide a perforation sequence, which is preferably performed by means of a suitable tool 30 (Figure 3). Preferably, the tool has a shaped grip, for example triangular, having a dimension such as to contact during the perforation an edge of recesses 21, also having a calibrated geometry and dimension. In such position, the tool is in the position of maximum advancement towards the bottom of corresponding recess 12 and also a height between a perforation head of the tool and the abutment position between the shaped grip and the edge of recess 21 is pre-defined in so as to perforate recess 21 in a pre-defined manner and depth independent of the user that performs the operation. Figure 3 further illustrates a stick 40 on which the primary antibodies, e.g. through a membrane facing a window 41, are applied. Through the window 41, the antibodies are exposed to the substances contained in recesses 11, 12 to
define any antigens, e.g. cancer antigens.
Figure 3 further illustrates an exploded view of the main components of the kit, i.e. supports 10 and 20 and a base 50 preferably with a double basin. Supports 10 and 20 are preferably arranged in pocket 51 so that the recesses 11, 12 are suspended when support 10 abuts against an edge of the pocket. Stick 40, perforation tool 30, the collection tool and a Pasteur pipette are preferably arranged in pocket 52.
Base 50 is preferably closed by means of a preferably square-shaped band casing which slides laterally with reference to the point of view of Figure 3.
With reference to what is illustrated in Figures 2 and 3, the kit can be adapted e.g. by number of biphasic containers and/or recesses, dehydrated or dried substances and liquids, to test methods made for other diseases.
Again with reference to Figure 3, preferably, support 20 or in an embodiment not shown support 10, comprises one or more spacer projections D having a calibrated vertical dimension and such as to define the adapted position wherein recesses 21 are housed in the corresponding recesses 12. In this way, it is easily identified e.g. by abutting the relative vertical position to perform the perforation by means of tool 30. Furthermore, as again visible in Figure 3, recesses 21 have a vertical dimension greater than that of the spacer projections D so that an end portion T of recesses 21 is within recesses 12. According to a preferred embodiment, pocket 52 houses at least one pipette, preferably a Pasteur pipette, in order to transfer the liquid from one recess 11, 12 to the other. Preferably, pocket 51 has a stepped profile and, correspondingly, support 10 has a lower width LI so as to rest a first step G1 of a width L2 of support 20. The latter abuts on a step G2 arranged above the step G1 when the kit is placed on a table.
EXAMPLES
EXAMPLE 1 - The cancer marker PRAME
The method for the early diagnosis and monitoring of melanoma of the present patent provides for the detection of the antigen expressed mainly in human melanomas (PRAME) in samples collected from suspected naevi of the subject under examination. The PRAME marker in the context of the present invention also includes variants, isoforms etc. Said marker is characterized by an NCBI Access number and the antibodies
used for the preparation of the device preferably refer to the following collected purely by way of example: PRAME Monoclonal Antibody (CL5148) (Product # MA5-31409); PRAME Polyclonal antibody, N-term Cat No. GTX45142; Mouse IgG (Fc fragment) antibody, F (ab') 2 fragment, pre-adsorbed (AP) Cat No. GTX25880 (Goat, Polyclonal) or Goat Anti-Mouse IgG antibody (HRP) Cat No. GTX 213211-01.
EXAMPLE 2 - PVDF strip preparation protocol
The steps for preparing the PVDF strip armed with the primary antibodies of interest in sequence are as follows: hydration of the PVDF strip (ThermoFisher Scientific Catalog Number LC2002) with methanol for 5 min; washing with water for 5 min; two washes with PBS for 5 min; incubation with protein A from Staphylococcus aureus (Sigma- Aldrich, 10 pg / mL) for 1 h in PBS; two washes with PBS; blocking with 3% BSA solution in PBS for 1 h; three washes with PBS for 5 min; assembly of the PVDF; incubation with rabbit antibody solution (PRAME Rabbit Polyclonal antibody, N-term Cat No. GTX45142), stirred O.N .; three washes with PBS for 5 min; two washes of the filter with PBS TEA 0.2M; incubation with 25mM DMP in 0.2M TEA HC1 pH 8.2; incubation with 0.2 M TEA + 20 mM ethanolamine; two washes with PBS for 5 min; storage in 0.02 NaN3 in PBS; after appropriate cutting of the filter, the individual strips, with dimensions of approximately 0.4 x 0.3 cm, will be mounted on the device support. Then it will proceed with the ELISA method in order to highlight the specific antigen present in the cytological sample tested. The Positive Control (CTR +) is an anti-actin antibody (Sigma - Aldrich, A2066).
EXAMPLE 3 - Device description
The various components of the kit equipped with cytobrush for the collection of biological material and support for the PVDF (Immobilon) strip armed with the primary antibodies of interest are described below.
The kit box is organized in rows of nine wells/stations containing buffers, lysing systems, detection systems stable at room temperature and dried/lyophilized antibodies stable at room temperature (Fig. 1).
EXAMPLE 4 - How to use the kit
The following are the operational steps which in sequence allow the diagnosis of melanoma or another pathology: collecting the sample from the suspect naevus, using the collection tools within the kit; immersing the biological sample for 15 min in the well/station number zero containing the lysis buffer; extracting the tool and transfering the lysate to the well/station number one; opening the package of the support to which the PVDF membrane is adhered; immersing the support with the PVDF strip for 5 min in the first well/station number one to allow the interaction of the proteins (antigens) with the primary antibodies adhered to the PVDF strip, in order to form the immunocomplex (purely by way of example: PRAME Polyclonal antibody, N-term Cat No. GTX45142; subsequently, the PVDF membrane is i mersed in well/station number two containing in solution the second primary mouse antibody (purely by way of example: PRAME Monoclonal Antibody (CL5148) (Product # MA5-31409) for the reaction with the immobilized immunocomplex; proceed with 2 washes of the support with the PVDF strip in wells containing T-PBS-buffer to eliminate the non- specifically attached proteins to the immunocomplex; immersion of the support with the PVDF strip for 10 min in well/station number five containing the mouse secondary antibody (purely by way of example: Mouse IgG (Fc fragment) antibody, F (ab') 2 fragment, pre-adsorb and (AP) Cat No. GTX25880 (Goat, Polyclonal) equipped with a detector enzymatic system (alkaline phosphatase or peroxidase); 2 washes of the support with the PVDF strip in wells/stations number six and seven containing T-PBS-buffer to eliminate excess secondary antibody; immersion of the support with the PVDF strip in the well/station number eight containing the substrate (BCIP / NBT, stable at room temperature or Luminol ECL substrate) necessary for the colorimetric reaction; interpretation of the result.
EXAMPLE 5 - Signal amplification as a function of temperature.
The colorimetric test will be carried out at room temperature, corresponding to a temperature range between 20° and 30° C. The use, in the kit, of a secondary antibody having a detector enzymatic system (alkaline phosphatase or peroxidase) has in this temperature range the maximum enzymatic activity, thus allowing an optimal signal amplification.
EXAMPLE 6 - Use of the kit of the invention for the identification of an individual with melanoma.
In the I.L.S. mode the Operator, after having highlighted the suspected lesion by means of an epilluminescence examination, places the cytobrush on it and performs the sampling maneuver. The maneuver consists in rotating the cytobrush on itself 4-5 times, exerting constant pressure. This method of cell collection is totally safe and free from any iatrogenic type problem. This technique can also be used to perform mass screening on populations, given that such neoplasm ranks fourth by incidence in the world. Thanks to this protocol it is possible to implement the correct principles for primary prevention.
The exam can be performed by qualified personnel after having performed a learning trial on the collection method.
Claims
1. Kit comprising a first support (10) having a first plurality of recesses (11) housing predefined quantities of substances and a second plurality of recesses (12) housing a first predefined quantity of at least one first primary antibody dehydrated or lyophilized to form an antigen/primary antibody system in contact with a biological sample and a second predefined quantity or a dehydrated or lyophilized secondary antibody provided with an enzyme system to form a complex with the antigen/primary antibody system which, following a chemical reaction, generates a chemocolorimetric response and/or bioluminescent with respect to a control sample or a dehydrated or lyophilized protease inhibitor; a second support (20) having a further plurality of recesses (21) each housing a lysis solution or a buffer solution and superimposable on the first support (10) so that the further recesses (21) are inside said second plurality of recesses (12); a first peelable covering layer (13) applied at least on the first plurality of recesses (11) and a second peelable covering layer (22) applied on the second support (20) to cover the further plurality of recesses (21), the second covering layer (22) presenting a group of symbol (SI, S2, S3) each representing a perforation point of the second covering layer (22) and of the further recesses (21) so that, after the perforation of the further recesses (21), the dehydrated or lyophilized antibodies are fluidified.
2. Kit according to claim 1, wherein the group of symbols, as a whole is representative of a perforation sequence.
3. Kit according to any one of claims 1 or 2, wherein the first covering layer (13) is a single body and has openings (A) each of which surrounds a corresponding recess (12) of the second plurality of recesses.
4. Kit according to any one of the preceding claims, wherein the second covering layer (22) adheres to the second support (20) by means of an adhesive and the adhesive is applied so as to be absent above the further recesses (21) when the second covering layer (22) adheres to the second support (20).
5. Kit according to any one of the preceding claims, wherein a spacer projection (D) is arranged between the first and second support (10, 20) to define by means of an abutment a relative position such that said further recesses (21) are internal to said second plurality of recesses
10
(12).
6. Kit according to any one of the preceding claims, comprising a base (50) defining a pocket (51) for housing said first and second supports (10, 20), the pocket having a first and a second step (Gl, G2) and the first and second support (10, 20) having corresponding first and second width (LI, L2) wherein the second width is greater than the first width and the first and second step (Gl, G2) are vertically spaced to define an abutment for the corresponding first and second support (10, 20) while said further recesses (21) are internal to said second plurality of recesses (12).
7. Kit according to any one of the preceding claims, comprising a stick (40) for immobilizing a second selective primary antibody of the same antigen of the first primary antibody; wherein the first and second primary antibody come from two different animal species; and wherein the secondary antibody is directed against one of the two species of animals from which the primary antibodies come.
8. Kit according to claim 7, comprising a window (41) and wherein the second primary antibody is immobilized on the window.
9. Kit according to claim 8, wherein the first antibody is monoclonal and the second antibody is polyclonal.
10. Kit according to any one of the preceding claims, wherein said substances of said first plurality of recesses (11) are at least a buffer solution in at least one of the first plurality of recesses (11) and a detecting substance in at least another of the first plurality of recesses (11), wherein the detector substance reacts with the enzymatic group to generate the chemocolorimetric and/or biolumine scent effect.
11. Kit according to any one of the preceding claims, wherein at least said first primary antibody is stable at room temperature.
12. Kit according to any one of the preceding claims, wherein the primary antibodies are anti- PRAME.
13. Kit according to claim 12, comprising a hard bristle cytobrush for collecting a biological sample of epithelium from a naevus.
11
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IT202100010463 | 2021-04-26 | ||
PCT/IB2022/053874 WO2022229849A1 (en) | 2021-04-26 | 2022-04-26 | Patient side in vitro screening kit for rapid diagnosis of a pathology |
Publications (1)
Publication Number | Publication Date |
---|---|
EP4330675A1 true EP4330675A1 (en) | 2024-03-06 |
Family
ID=77021931
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP22725534.6A Pending EP4330675A1 (en) | 2021-04-26 | 2022-04-26 | Patient side in vitro screening kit for rapid diagnosis of a pathology |
Country Status (2)
Country | Link |
---|---|
EP (1) | EP4330675A1 (en) |
WO (1) | WO2022229849A1 (en) |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AT5044U1 (en) * | 2001-05-10 | 2002-02-25 | Medsystems Diagnostics Gmbh | QUANTITATIVE ONE-STEP IMMUNITY TEST IN LYOPHILIZED FORM |
EP2501724B1 (en) * | 2009-11-18 | 2015-11-18 | MannKind Corporation | Monoclonal antibodies and diagnostic uses thereof |
US9839910B2 (en) * | 2014-09-29 | 2017-12-12 | Illumina, Inc. | Fluidic cartridges, systems, and methods for conducting biochemical reactions |
EP3297673A4 (en) * | 2015-05-22 | 2019-05-08 | Memorial Sloan-Kettering Cancer Center | T cell receptor-like antibodies specific for a prame peptide |
-
2022
- 2022-04-26 WO PCT/IB2022/053874 patent/WO2022229849A1/en active Application Filing
- 2022-04-26 EP EP22725534.6A patent/EP4330675A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
WO2022229849A1 (en) | 2022-11-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP4253344B2 (en) | Fluid sample analyzer with sealable sample storage reservoir | |
JP6722699B2 (en) | Biological sample collection and analysis device and method of using the same | |
US4770853A (en) | Device for self contained solid phase immunodiffusion assay | |
EA037737B1 (en) | Collection device for diagnostics of vaginal discharge | |
AU2011293832A1 (en) | Biological fluid sampling and storage apparatus for remote use | |
EP3230738A2 (en) | Test apparatus and methods for st2 cardiac biomarker | |
KR20120124320A (en) | Apparatus and manufacturing method of a diagnostic kit with the sample of urine to diagnose the prostate cancer | |
HU228066B1 (en) | Allergen microarray assay | |
JP2676108B2 (en) | Immunoenzymatic detection of substances from blood drops or fluids from any biological medium | |
JPWO2012137832A1 (en) | Pancreas examination method and pancreas examination kit | |
EP1051616A2 (en) | Integrated collection and assay device for saliva and blood | |
US20090042313A1 (en) | Recording assay device | |
WO2005106018A1 (en) | Direct assay of skin cholesterol in skin samples removed by tape stripping | |
US10605809B2 (en) | Rapid test for the qualitative and/or quantitative analysis of antibodies against human papilloma viruses (HPV) present in body fluid, and device for carrying out the rapid test | |
US20120094371A1 (en) | Test strip for h. pylori detection | |
EP4330675A1 (en) | Patient side in vitro screening kit for rapid diagnosis of a pathology | |
Green et al. | Enumeration and detection of aerosolized Aspergillus fumigatus and Penicillium chrysogenum conidia and hyphae using a novel double immunostaining technique | |
US8690792B2 (en) | Direct assay of cholesterol in skin removed by tape stripping | |
CN209387663U (en) | P16/Ki-67 combines cervical carcinoma detection kit | |
CN201497742U (en) | Immunogold filtration assay kit for combined detection of EA-IgG antibody and VCA-IgA antibody against EB virus | |
US20100304397A1 (en) | Chromogenic test kit for detecting health conditions in saliva | |
Sadowski et al. | Evaluation of the FlexSure HP whole blood antibody test for diagnosis ofHelicobacter pyloriinfection | |
Galan et al. | Detection of Borrelia in Ixodes scapularis ticks by silver stain, immunohistochemical and direct immunofluorescent methods | |
RU2525428C2 (en) | Diagnostic technique for tuberculosis | |
Chang | A Comparison of Rapid Stain Identification Test for Semen (RSIDTM-Semen), Seratec® PSA Semiquant, and ABAcard® p30 Tests for the Forensic Identification of Seminal Fluid |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: UNKNOWN |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
17P | Request for examination filed |
Effective date: 20231124 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
DAV | Request for validation of the european patent (deleted) | ||
DAX | Request for extension of the european patent (deleted) |